Comparing Mymd Pharmaceuticals (NASDAQ:QCLS) & AstroNova (NASDAQ:ALOT)
by Michael Walen · The Markets DailyAstroNova (NASDAQ:ALOT – Get Free Report) and Mymd Pharmaceuticals (NASDAQ:QCLS – Get Free Report) are both small-cap technology companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.
Volatility & Risk
AstroNova has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Mymd Pharmaceuticals has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.
Valuation & Earnings
This table compares AstroNova and Mymd Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AstroNova | $150.51 million | 1.51 | -$2.38 million | ($0.18) | -160.78 |
| Mymd Pharmaceuticals | N/A | N/A | -$11.63 million | ($20.69) | -0.14 |
AstroNova has higher revenue and earnings than Mymd Pharmaceuticals. AstroNova is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current recommendations for AstroNova and Mymd Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AstroNova | 1 | 0 | 0 | 0 | 1.00 |
| Mymd Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Insider and Institutional Ownership
43.0% of AstroNova shares are held by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are held by institutional investors. 12.6% of AstroNova shares are held by company insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares AstroNova and Mymd Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AstroNova | -0.88% | 2.94% | 1.61% |
| Mymd Pharmaceuticals | N/A | -76.40% | -35.10% |
Summary
AstroNova beats Mymd Pharmaceuticals on 7 of the 10 factors compared between the two stocks.
About AstroNova
AstroNova, Inc. designs, develops, manufactures, and distributes specialty printers, and data acquisition and analysis systems in the United States, Europe, Asia, Canada, Central and South America, and internationally. The company operates in two segments, Product Identification (PI) and Test & Measurement (T&M). The PI segment offers tabletop and production-ready digital color label printers, and OEM printing systems under the QuickLabel brand; digital color label mini-presses and inline printing systems under the TrojanLabel brand; and label materials, tags material, inks, toners, and thermal transfer ribbions under the GetLabels brand. This segment also develops and licenses various specialized software programs to design and manage labels and print images; and provides training and support. This segment serves chemicals, cosmetics, food and beverage, medical products, nutraceuticals, pharmaceuticals, and other industries; and brand owners, label converters, commercial printers, and packaging manufacturers. The T&M segment offers airborne printing solutions, such as ToughWriter used to print hard copies of navigation maps, arrival and departure information, flight itineraries, weather maps, performance data, passenger data, and various air traffic control data; ToughSwitch, an ethernet switches used to connect multiple computers or Ethernet devices; TMX data acquisition systems; Daxus DXS-100 distributed data acquisition platform; SmartCorder DDX100 portable data acquisition systems for facility and field testing; and Everest EV-5000, a digital strip chart recording system used primarily in aerospace and defense. This segment serves aerospace and aerospace and defense, automotive, commercial airline, energy, manufacturing, and transportation industries. The company was formerly known as Astro-Med, Inc. and changed its name to AstroNova, Inc. in May 2016. AstroNova, Inc. was incorporated in 1969 and is headquartered in West Warwick, Rhode Island.
About Mymd Pharmaceuticals
TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.